Depression and anxiety after 2 years of follow-up in patients diagnosed with diabetes or rheumatoid arthritis

Gåfvels, Catharina; Hägerström, Margareta; Rane, Kristina; Wajngot, Alexandre; Wändell, Per

doi:10.1177/2055102916678107

Cited by 11 publications

(8 citation statements)

References 63 publications

(90 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Частота РТДС варьирует в работах разных авторов от 15 до 89% [3,[7][8][9][10], что связано не только с особенностями выборки, но и с различными способами их ди-агностики. В большинстве исследо-ваний диагностика РТДС проводит-ся с помощью опросников, которые, являясь достаточно субъективным инструментом оценки, как правило, занижают реальную частоту депрес-сивных и тревожных расстройств.…”

Section: Discussionunclassified

See 1 more Smart Citation

Effects of Synthetic Disease-Modifying Antirheumatic Drugs, Biological Agents, and Psychopharmacotherapy on the Mental Disorders in Patients With Rheumatoid Arthritis

Абрамкин¹,

Лисицына²,

Veltishchev

et al. 2017

Naučno-praktičeskaâ revmatologiâ

View full text Add to dashboard Cite

Mental disorders (MDs) of the anxiety-depressive spectrum (ADS) and cognitive impairment (CI) are characteristic of the majority of patients with rheumatoid arthritis (RA); however, the effects of disease-modifying antirheumatic drugs (DMARDs), biological agents (BAs), and their combinations with psychopharmacological drugs (PPDs) on these abnormalities have been insufficiently studied. Objective: to investigate trends in the incidence of MDs in RA patients receiving different treatment regimens.Subjects and methods. The investigation included 128 RA patients (13% men and 87% women) who fulfilled the 1987 American College of Rheumatology criteria; their mean age was 47.4±0.9 years; the median duration of RA was 96 [48; 228] months. RA activity was found to be high, moderate, and low in 48, 56, and 24 patients, respectively. DAS28 averaged 5.34±0.17. 80% of the patients received DMARDs. MDs were diagnosed based on ICD-10 coding, by using a semi-structured interview and scales, such as the Hospital Anxiety and Depression Scale, the Hamilton Anxiety Scale, and the Montgomery-Asberg Depression Rating Scale. Clinical and psychological procedures were used to diagnose CI. At the study inclusion stage, ADS disorders were detected in 123 (96.1%) patients; CI was found in 88 (68.7%). Forty-one (32.1%) patients were diagnosed with major depression (an obvious or moderate depressive episode), 53 (41.4%) patients had minor depression (a mild depressive episode and dysthymia), and 29 (22.6%) had anxiety disorders (ADs) (adjustment disorders with anxiety symptoms, as well as generalized anxiety disorder). The dynamics of MDs was estimated in 112 (87.5%) of the 128 patients and in 83 (64.8%) at one- and five-year follow-ups, respectively. The following groups were identified according to the performed therapy: 1) synthetic DMARDs (n = 39); 2) synthetic DMARDs + PPDs (n = 43); 3) BAs + DMARDs (n = 32); 4) BAs + DMARDs + PPDs (n = 9).Results and discussion. In Group 1, the frequency of major depression increased insignificantly from 25% to 32.2 and 33.3% (p = 0.36) at one- and five-year follow-ups, respectively; that of minor depression decreased from 51% to 48.4 (p = 0.5) and 50% (p = 0.6) respectively; the number of patients with ADs declined significantly from 24% to 3.2 (p = 0.018) and 4.2% (p = 0.021), respectively. The frequency of CI rose from 63.5% to 64.5 and 81.8%, respectively (p = 0.12). In Group 2, the frequency of major depression decreased from 43 to 19% (p = 0.049) at one-year follow-up; and none of the patients was found to have ADS disorders at five-year follow-up (p < 0.001); the frequency of minor depression dropped from 38% to 23.8 and 7.1% at one-year (p = 0.35) and five-year (p = 0.002) follow-ups, respectively; the frequency of ADs fell from 19% to 4.8 (p = 0.044) and 0% (p = 0.012), respectively. The frequency of CI decreased insignificantly from 80.9% to 76.2 (p = 0.39) and 61.5% (p = 0.061), respectively. In Group 3 treated with BAs, the frequency of major depression increased statistically insignificantly from 31.2% to 37.9 (p = 0.39) and 42.8% (p = 0.28) at oneand five-year follow-ups, respectively; the frequency of minor depression rose insignificantly from 37.5% to 48.3 (p = 0.28) and 52.4% (p = 0.21), respectively; and that of ADs dropped from 25 to 0% at one-year (p = 0.003) and five-year (p = 0.011) follow-ups. Moreover, the frequency of CI increased from 75% up to 79.3 (p = 0.46) and 90% (p = 0.16) at one- and five-year follow-ups respectively. In Group 4, the frequency of major depression decreased significantly from 66.7 to 22.2% (p = 0.076) and complete regression (p = 0.004) at one- and five-year follow-ups, respectively; that of minor depression increased slightly from 11.1 to 33.3% (p = 0.28) due to the transformation of major depression into minor one at one- and five-year follow-ups, respectively; the frequency of ADs fell from 22.2% to zero at 5 years; and the incidence of CI declined 66.7 to 57.1% (p = 0.54).Conclusion. Synthetic DMARDs had no effect on the ADS disorders and CI in patients with RA; BAs promoted the regression of ADs and did not affect the progression of depression and CI. A combination of DMARDs and BAs used at the adequate dose of PPDs for the same period led to the regression of ADS disorders and the reduction in the frequency of CI.

show abstract

Section: Discussionunclassified

“…Частота встречаемости депрессивных рас-стройств при РА достигает 40-70%, в том числе большой депрессии (БД) -порядка 13-30%, а ТР -20-46% [3,[7][8][9][10]. Распространенность всех ПР у больных РА, по дан-ным ФГБНУ НИИР им.…”

unclassified

Effects of Synthetic Disease-Modifying Antirheumatic Drugs, Biological Agents, and Psychopharmacotherapy on the Mental Disorders in Patients With Rheumatoid Arthritis

Абрамкин¹,

Лисицына²,

Veltishchev

et al. 2017

Naučno-praktičeskaâ revmatologiâ

View full text Add to dashboard Cite

show abstract

“…Acne vulgaris is a common dermatological condition that affects physical and psychological aspects of patients [116]. Several diseases that show the presence of a certain degree of acne also relate with depression and emotional stress such as type-2 diabetes, rheumatoid arthritis, and polycystic ovarian syndrome (PCOS) [117][118][119]. Pathophysiology of this disease involves several key mechanisms including excessive sebum production due to hormonal and environmental conditions, alteration of fatty acids composition due to sebum metabolism by Cutibacterium acnes, hyperkeratinization within the follicle that clogs up the pore in the form of whitehead or blackhead comedones, inflammation induced by bacterial colonization, and malfunction of locale innate and adaptive immune system [120].…”

Section: Biological Activities Of Chromium 41 Acne Vulgaris (Antiacne)mentioning

confidence: 99%

Dermatologic Toxicities and Biological Activities of Chromium

Jumina¹,

Harizal²

2021

Trace Metals in the Environment - New Approaches and Recent Advances

View full text Add to dashboard Cite

Chromium is a versatile metal with various industrial applications and biological activities. However, as a transition metal, this element forms several species, i.e. oxidation states of −4 to +6, with different degrees of toxicities that affect ecosystems and organisms including human beings. The skin is the outermost organ that usually interacts directly with chromium species in nature. These contact and interaction induce the formation of several acute and chronic negative effects including contact dermatitis, skin cancer, allergy, etc. In this chapter, toxicity and biological activity of several chromium species, such as chromium zero-valent, trivalent, hexavalent, will be reviewed to obtain better comprehension in chromium toxicity. Sources and routes of exposure, toxicity and possible treatment, and biological activity on the skin are arranged and explained systematically.

show abstract

“…Известно, что расстройства тревожно-депрессивного спектра (РТДС) являются наиболее частой и важной коморбидной проблемой РА [6]. Частота встречаемости депрессивных расстройств среди больных РА варьирует от 22 до 85,2%, тревожных -от 24 до 84,1% [7][8][9][10]. По данным ФГБНУ «НИИР им.…”

Section: ââåäåíèåunclassified

Depression and severity of articular destruction in patients with rheumatoid arthritis

Абрамкин

Лисицына

Veltishchev

et al. 2020

Terapevticheskii arkhiv

View full text Add to dashboard Cite

Aim. To assess the influence of anxiety and depressive disorders on joint destruction in patients with rheumatoid arthritis (RA). Materials and methods. 128 RA-patients were included, 87% were women with a mean age of 47.411.3 years and a median of RA duration 96 [48; 228] months. At the inclusion most patients had moderate (n=56, 43.7%) and severe (n=48, 37.5%) disease activity according to DAS28. Joint destruction was classified as maximal in patients with radiographic stage III, IV and/or osteonecrosis) and minimal in patients with stage I, II and no osteonecrosis. Pain intensity was measured with the BPI (Brief Pain Inventory) scale, severity of fatigue with fatigue severity scale (FSS), clinically important fatigue was diagnosed in patients with FSS4. Anxiety and depressive disorders (ADD) were diagnosed by a licensed psychiatrist in 123 (96.1%) of RA-patients in accordance with ICD-10 in semi-structured interview. Severity of depression and anxiety was evaluated with Montgomery-Asberg Depression Rating Scale (MADRS) and Hamilton Anxiety Rating Scale (HAM-A). RA-patients with ADD were divided into the following treatment groups: 1 сDMARDs (n=39), 2 сDMARDs+PPT (sertraline or mianserine), n=43, 3 сDMARDs+bDMARDs (n=32), 4 сDMARDs+bDMARDs+PPT (sertraline or mianserine), n=9. Biologics treatment duration varied from 1 to 6 years, antidepressants from 6 to 96 weeks. 83 (67.5%) RA patients were assessed at five-years follow-up. Linear regression analysis was conducted to determine factors associated with maximal join destruction. Results. According to linear regression analysis, maximal joint destruction at 5 years follow-up was associated with higher baseline BPImax, longer RA and ADD duration, clinically important fatigue at baseline, baseline extraarticular RA manifestations, recurrent depressive disorder at 5-years follow-up and treatment with cDMARDs only. Conclusion. Recurrent depressive disorder without antidepressant treatment is an important predictor of progression of joint destruction in patients with rheumatoid arthritis.

show abstract

Depression and anxiety after 2 years of follow-up in patients diagnosed with diabetes or rheumatoid arthritis

Cited by 11 publications

References 63 publications

Effects of Synthetic Disease-Modifying Antirheumatic Drugs, Biological Agents, and Psychopharmacotherapy on the Mental Disorders in Patients With Rheumatoid Arthritis

Effects of Synthetic Disease-Modifying Antirheumatic Drugs, Biological Agents, and Psychopharmacotherapy on the Mental Disorders in Patients With Rheumatoid Arthritis

Dermatologic Toxicities and Biological Activities of Chromium

Depression and severity of articular destruction in patients with rheumatoid arthritis

Contact Info

Product

Resources

About